Clinical Study Of Entecavir Combined With Novo Rapid30 In The Treatment Of Hepatitis B-related Hepatic Diabetes

Objective:This article will systematically study the clinical efficacy of Entecavir combined with Novo Rapid30 on hepatitis B-related liver-induced diabetes mellitus(HD),in the hope that it will not enrich clinical treatment of hepatitis B-related diabetes and provide more rough plans.Methods:120 patients with hepatitis B-related HD treated in Qing Dao No.6 People,s Hospital from March 2016 to March 2018 were selected as the research subjects.They were divided into control group,oral hypoglycemic agent group and insulin group according to the treatment plan.There were 40 cases in each group.The three groups of patients received symptomatic treatment of liver protection and diabetes diet and exercise guidance at the beginning of admission.On this basis,the control group was given entecavir(0.5 mg orally,once daily)for treatment.The oral hypoglycemic group was treated with entecavir and glucobay.The insulin group was given entecavir and Novo Rapid30,the initial dose can be 0.4-0.5U /(kg · d),or the dose can be adjusted according to the fasting blood glucose index of the patient,which is injected daily by subcutaneous injection 2 times,30 min before breakfast and dinner)for treatment.The virological response rate and diabetes control rate of the three groups of patients were compared.Patients in all three groups were treated continuously for 6 months.Observation and analysis of the virological response rate and diabetes control rate before and after treatment in the three groups of patients.Results:(1)There were no significant adverse reactions in the control group,the oral hypoglycemic drug group,and the insulin treatment group.After treatment,the glycated hemoglobin and fasting blood glucose of the patients in the oral hypoglycemic drug group and the insulin treatment group were lower than those in the control group.Compared with the oral hypoglycemic drug group,the insulin treatment group had better blood glucose control.The patients in the control group,the oral hypoglycemic drug group,and the insulin treatment group had no severe hypoglycemia.The difference was statistically significant,P <0.05.(2)The hepatitis B virus load in the control group,the oral hypoglycemic drug group,and the insulin treatment group decreased after treatment compared with that before treatment.Compared with the control group,the oral hypoglycemic drug group and the insulin treatment group had a higher virus response rate.And compared with the oral hypoglycemic drug group,the insulin treatment group had a higher virus response rate.The difference was statistically significant,P <0.05.(3)The liver function of the control group,the oral hypoglycemic drug group,and the insulin treatment group recovered after treatment compared with that before treatment.Compared with the control group,the liver function recovery was better in the oral hypoglycemic drug group and the insulin treatment group.And compared with the oral hypoglycemic drug group,the insulin treatment group had better liver function recovery.The difference was statistically significant,P <0.05.Conclusion:Entecavir combined with Novo Rapid30 in patients with hepatitis B-related liver-induced diabetes can improve their liver function and control blood glucose levels,which is worth promoting.